When the 0.5-fold, 0.5-fold, and 2.5-fold values of the median expression value in noncancerous tissue samples of each organ were used as cut-off values to dichotomize the NEIL1, NEIL2, and NEIL3 expression values in the cancer cases, respectively, cancers with reduced NEIL1 expression, reduced NEIL2 expression, and elevated NEIL3 expression were detected in 31.4%, 9.0%, and 79.4% of all cancers, respectively (Supplementary Table S3). This evidence concerns the gene NEIL1 and cancer.